Entrada TherapeuticsTRDA
About: Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
Employees: 168
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
282% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 11
55% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 11
33% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 4 (+1) [Q2]
14% more capital invested
Capital invested by funds: $370M [Q1] → $423M (+$52.5M) [Q2]
8% more funds holding
Funds holding: 77 [Q1] → 83 (+6) [Q2]
2.12% more ownership
Funds ownership: 77.78% [Q1] → 79.91% (+2.12%) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Oppenheimer Francois Brisebois 70% 1-year accuracy 21 / 30 met price target | 43%upside $25 | Outperform Reiterated | 26 Aug 2024 |
HC Wainwright & Co. Raghuram Selvaraju 48% 1-year accuracy 141 / 295 met price target | 3%upside $18 | Buy Reiterated | 14 Aug 2024 |